Nordic Nanovector
Nordic Nanovector management expresses strong confidence in the Company (Cision)

2016-12-08 15:46
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN. Oslo, Norway, 8 December 2016 Following the latest press releases from Nordic Nanovector ASA (the "Company"), the management and the board of directors of the Company wish to express their continued support and confidence in the Company going forward. All members of management and board members are committed to the Company and furthermore are subject to the 180 day lock-up undertakings as previously announced. Regarding Jostein Dahle's sale of shares yesterday, he states the following: “I would like to emphasize that this transaction was based solely on my personal decision, motivated by my personal financial obligations. I did not anticipate the unfortunate consequences of my decision and the effects it could have on the market when made at this time. As one of the founders of the Company, I remain strongly committed to Nordic Nanovector and continue to have strong confidence in its technology and prospects. After the transaction, I own 204,958 shares and 135,000 options in Nordic Nanovector, confirming my dedication and commitment to the Company.” The Company also hereby announces that the following primary insiders will seek to buy shares in the market commencing today for the approximate amounts listed below: Luigi Costa (CEO) – NOK 670,000 Tone Kvåle (CFO) – NOK 200,000 Lisa Rojkjaer (CMO) – NOK 250,000 Anniken Hagen (CTOO) – NOK 200,000 Rita Dege (CHRO) – NOK 200,000 In addition, Jon Frode Vaksvik, a related party to Tone Kvåle, CFO of Nordic Nanovector ASA, has on 8 December 2016 purchased 3,000 shares in the Company at an average share price of NOK 102.48 per share. Following the transaction, Tone Kvåle and related parties will together hold 177,854 shares in the Company and Tone Kvåle holds 210,000 options in the Company. This information is subject to duty of disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act. For further information, please contact: For Nordic Nanovector IR enquiries: Luigi Costa, Chief Executive Officer Cell: +41 79 124 8601 Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com Media enquiries: Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 282 2948/+44 207 282 2949 Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab, conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its pipeline of innovative targeted immunoconjugate therapies for multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Important Notices This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. This document is not for publication or distribution in the United States of America, Canada, Australia or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the “Securities Act”)) or to publications with a general circulation in the United States of America. This document is not an offer for sale of securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under Securities Act. Nordic Nanovector does not intend to register any part of the offering in the United States, There will be no public offering of the securities in the United States of America. Any public offering in the United States would be made by means of a prospectus containing detailed information about the company and management, as well as financial statements. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an “EEA Member State”) that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive. Investing in securities involves certain risks. You should read the Risk Factors contained in the prospectus dated 10 March 2015 (available at http://www.nordicnanovector.com/investor-relations/reports-and-presentations/prospectus), but they should be read in light of any new or additional information contained in any further publicly available information since the date of the prospectus. This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Nordic Nanovector and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Nordic Nanovector assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Thor Medical - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -